Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?

#	Paper	IF	Citations
159	Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. **2015**, 7, 157-67		19
158	Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment. **2016**, 10, 1945-1956		27
157	Tolerogenic Vaccination with MOG/VitD Overcomes Aggravating Effect of C. albicans in Experimental Encephalomyelitis. **2016**, 22, 807-16		7
156	Expression of IL-1 in rhesus EAE and MS lesions is mainly induced in the CNS itself. **2016**, 13, 138		43
155	Refractory autoimmune disease: an overview of when first-line therapy is not enough. **2016**, 53 Suppl 1, S35-8		1
154	Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod. **2016**, 16, 129		19
153	Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study. **2016**, 263, 1802-9		13
152	Blockade of CD47 ameliorates autoimmune inflammation in CNS by suppressing IL-1-triggered infiltration of pathogenic Th17 cells. **2016**, 69, 74-85		22
151	Combined exercise training reduces fatigue and modulates the cytokine profile of T-cells from multiple sclerosis patients in response to neuromediators. **2016**, 293, 91-99		38
150	Dimethyl Fumarate: A Review in Relapsing-Remitting MS. **2016**, 76, 243-54		29
149	Deficits in Social Cognition: An Unveiled Signature of Multiple Sclerosis. **2017**, 23, 266-286		42
148	What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question. **2017**, 120, 279-293		6
147	Efficiency of antibody therapy in demyelinating diseases. **2017**, 29, 327-335		14
146	[Real-world evidence : Benefits and limitations in multiple sclerosis research]. **2017**, 88, 1153-1158		3
145	Multiple sclerosis and rehabilitation: an overview of the different rehabilitation settings. **2017**, 38, 2131-2138		8
144	The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. **2017**, 264, 2351-2374		66
143	Need for symptomatic management in advanced multiple sclerosis. **2017**, 135, 529-532		10

142 Guideline for multiple sclerosis treatment in Brazil: Consensus from the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology. **2017**, 75, 57-65 — 5

141 Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. **2017**, 9, 251-260 — 70

140 Eicosapentaenoic Acid in Myelinogenesis. **2017**, 267-273

139 SPK1-transfected UCMSC has better therapeutic activity than UCMSC in the treatment of experimental autoimmune encephalomyelitis model of Multiple sclerosis. **2018**, 8, 1756 — 8

138 Rehabilitation in People with Progressive MS. **2018**, 253-274

137 Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment. **2018**, 34, 1419-1430 — 13

136 Targeting demyelination via ᵌ-secretases promoting sAPPᵌ release to enhance remyelination in central nervous system. **2018**, 109, 11-24 — 17

135 A systems medicine approach reveals disordered immune system and lipid metabolism in multiple sclerosis patients. **2018**, 192, 18-32 — 8

134 Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon. **2018**, 10, 723-730 — 4

133 A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients. **2018**, 14, 1765-1788 — 5

132 Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis. **2018**, 32, 1145-1157 — 21

131 Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing. **2018**, 45, 489-503 — 25

130 Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study. **2019**, 25, 1263-1272 — 26

129 Therapeutic Approaches toward Multiple Sclerosis: Where Do We Stand and Where Are We Headed?. **2019**, 2, 1900070 — 1

128 Use of glatiramer acetate between 2010-2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients. **2019**, 19, 159 — 2

127 Human ES-derived MSCs correct TNF-ᵅ mediated alterations in a blood-brain barrier model. **2019**, 16, 18 — 5

126 Design of biodegradable nanoparticles to modulate phenotypes of antigen-presenting cells for antigen-specific treatment of autoimmune disease. **2019**, 222, 119432 — 34

125 Computational Drug Repurposing Algorithm Targeting TRPA1 Calcium Channel as a Potential Therapeutic Solution for Multiple Sclerosis. **2019**, 11, — 10

124	Expert opinion: Criteria for second-line treatment failure in patients with multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2019**, 36, 101406	4	2
123	A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4 CD25 FOXP3 Regulatory T Cells in Myelin-Specific TCR Transgenic Mice Contingent Upon Low-Efficiency T Cell Antigen Receptor Recognition. *Frontiers in Immunology*, **2018**, 9, 3119	8.4	7
122	Pharmacoeconomics of synthetic therapies for multiple sclerosis. **2019**, 20, 1331-1340		6
121	Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-**2019**, 203, 696-704		4
120	A Review of Available Treatments, Clinical Evidence, and Guidelines for Diagnosis and Treatment of Pediatric Multiple Sclerosis in the United States. **2019**, 34, 612-620		3
119	Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS. *Multiple Sclerosis and Related Disorders*, **2019**, 33, 13-21	4	6
118	The potentials of umbilical cord-derived mesenchymal stem cells in the treatment of multiple sclerosis. **2019**, 30, 857-868		5
117	GP6 rs2304166 polymorphism is associated with response to natalizumab in multiple sclerosis patients. **2019**, 4,		
116	Therapeutic adherence and coping strategies in patients with multiple sclerosis: An observational study. **2019**, 98, e16532		10
115	Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran. **2019**, 22, 297-305		7
114	Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets. **2019**, 24, 428-439		47
113	Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis. *Multiple Sclerosis and Related Disorders*, **2019**, 27, 370-377	4	14
112	Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2019**, 29, 55-61	4	39
111	Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy. **2019**, 266, 306-315		9
110	Dynamics of IFN-Responses during Respiratory Viral Infection. Insights for Therapeutic Strategies. **2020**, 201, 83-94		35
109	Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. **2020**, 26, 1719-1728		8
108	To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2019**, 39, 101908	4	8
107	Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis. **2020**, 34, 65-92		10

| 106 | Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. **2020**, 26, 1866-1876 | | 12 |

| 105 | Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2020**, 46, 102507 | 4 | 0 |

| 104 | Recent Advances in Nanomedicines for Multiple Sclerosis Therapy.. **2020**, 3, 6571-6597 | | 3 |

| 103 | Exploiting relationships between outcomes in Bayesian multivariate network meta-analysis with an application to relapsing-remitting multiple sclerosis. **2020**, 39, 3329-3346 | | 0 |

| 102 | IFI35 as a biomolecular marker of neuroinflammation and treatment response in multiple sclerosis. **2020**, 259, 118233 | | 1 |

| 101 | Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study. *Multiple Sclerosis and Related Disorders*, **2020**, 46, 102438 | 4 | 7 |

| 100 | Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study. **2020**, 15, e0238476 | | 0 |

| 99 | Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study. *Multiple Sclerosis and Related Disorders*, **2020**, 46, 102518 | 4 | 3 |

| 98 | Selenization of S. cerevisiae increases its protective potential in experimental autoimmune encephalomyelitis by triggering an intestinal immunomodulatory loop. **2020**, 10, 22190 | | 3 |

| 97 | The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review. **2020**, 1352458520972557 | | 2 |

| 96 | Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project. *Pharmaceuticals*, **2020**, 13, | 5.2 | 1 |

| 95 | Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. **2020**, 12, 89-108 | | 6 |

| 94 | Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. *Multiple Sclerosis and Related Disorders*, **2020**, 43, 102158 | 4 | 2 |

| 93 | Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development. **2020**, 2020, 7191080 | | 22 |

| 92 | Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data. **2020**, 16, 1670-1676 | | 3 |

| 91 | Calcitriol Prevents Neuroinflammation and Reduces Blood-Brain Barrier Disruption and Local Macrophage/Microglia Activation. **2020**, 11, 161 | | 15 |

| 90 | Strategies for Neuroprotection in Multiple Sclerosis and the Role of Calcium. **2020**, 21, | | 9 |

| 89 | Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis. *Frontiers in Immunology*, **2020**, 11, 594 | 8.4 | 13 |

88	Listening to the neurological teams for multiple sclerosis: the SMART project. **2020**, 41, 2231-2240		5
87	Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study). *Multiple Sclerosis and Related Disorders*, **2020**, 42, 102124	4	5
86	DFT computational study towards investigating Cladribine anticancer drug adsorption on the graphene and functionalized graphene. **2020**, 31, 1691-1705		9
85	A literature review of biosensors for multiple sclerosis: Towards personalized medicine and point-of-care testing. *Multiple Sclerosis and Related Disorders*, **2021**, 48, 102675	4	1
84	DFT study of Ni-doped graphene nanosheet as a drug carrier for multiple sclerosis drugs. **2021**, 1196, 113114		3
83	Preventive neurology concepts for training the next-generation and closing gaps in real-world Multiple Sclerosis Care. *Multiple Sclerosis and Related Disorders*, **2021**, 47, 102631	4	2
82	Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. **2021**, 21, 131-140		4
81	Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. **2021**, 14, 1756286420982134		11
80	Fingolimod in pediatric multiple sclerosis: three case reports. **2021**, 42, 19-23		1
79	Insights for Fostering Resilience in Young Adults With Multiple Sclerosis in the Aftermath of the COVID-19 Emergency: An Italian Survey. **2020**, 11, 588275		4
78	Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. **2021**, 12, 647811		3
77	Efficacy classification of modern therapies in multiple sclerosis. **2021**, 10, 495-507		9
76	Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. *Multiple Sclerosis and Related Disorders*, **2021**, 49, 102717	4	4
75	The role of teriflunamide in multiple sclerosis patient: an observational study. **2021**, 1-8		1
74	Multiple sclerosis and aging: comorbidity and treatment challenges. *Multiple Sclerosis and Related Disorders*, **2021**, 50, 102815	4	5
73	Classification and visualization of longitudinal patterns of medication dose: An application to interferon-beta-1a and amitriptyline in patients with multiple sclerosis. **2021**, 30, 1214-1223		0
72	Description and preliminary experience with Virtual Visit Assessment (ViVA) during the COVID-19 pandemic, a structured virtual management protocol for patients with multiple sclerosis. **2021**, 1		3
71	Effects of Venlafaxine, Risperidone and Febuxostat on Cuprizone-Induced Demyelination, Behavioral Deficits and Oxidative Stress. **2021**, 22,		3

70	Progress in the Application of Drugs for the Treatment of Multiple Sclerosis. **2021**, 12, 724718		4
69	Creating a Real-World Data, United States Healthcare Claims-Based Adaptation of Kurtzke Functional Systems Scores for Assessing Multiple Sclerosis Severity and Progression. **2021**, 38, 4786-4797		1
68	Characterizing relapsing remitting multiple sclerosis patients burdened with hypertension, hyperlipidemia, and asthma. *Multiple Sclerosis and Related Disorders*, **2021**, 53, 103040	4	0
67	Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression. **2021**, 27, 1273-1295		0
66	Perspectives from the patient: A content analysis of communication changes, impact, and strategies to facilitate communication in multiple sclerosis. **2021**, 1-17		0
65	Diffusion Basis Spectrum Imaging Detects Axonal Loss After Transient Dexamethasone Treatment in Optic Neuritis Mice. **2020**, 14, 592063		
64	Clinical Decision-Making in the Management of Multiple Sclerosis. **2020**, 159-177		1
63	Nanobiotechnology in Neurodegenerative Diseases. **2019**, 65-138		3
62	Prognostic factors of disability in relapsing remitting multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2019**, 30, 9-16	4	30
61	The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy. **2017**, 23, 4230-4240		4
60	Living with Multiple Sclerosis in Europe: Pharmacological Treatments, Cost of Illness, and Health-Related Quality of Life Across Countries. 17-37		5
59	Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study. *Current Topics in Medicinal Chemistry*, **2020**, 20, 2391-2403	3	1
58	A self-management programme to reduce falls and improve safe mobility in people with secondary progressive MS: the BRiMS feasibility RCT. *Health Technology Assessment*, **2019**, 23, 1-166	4.4	6
57	Prognostic uncertainty in multiple sclerosis: A concept analysis. *Journal of Clinical Nursing*, **2021**,	3.2	
56	Strategy initiation of treatment for multiple sclerosis. *Neurologie Pro Praxi*, **2016**, 17, 236-239	0.2	
55	Multiple Sclerosis. **2017**,		
54	Detection of Active Plaques in Multiple Sclerosis using 3 and 12 Directional Diffusion-weighted Imaging: Comparison with Gadolinium-enhanced MR Imaging. *Journal of Biomedical Physics and Engineering*, **2020**, 10, 737-744	1	1
53	Suspensió de las terapias modificadoras de la enfermedad en esclerosis mItiple. Una aproximaci multidimensional. *Neurologia Argentina*, **2018**, 10, 232-240	0.1	

52	Long Term Compliance for MS Patients in Treatment with Disease Modifying Drugs (DMDs). *The Open Neurology Journal*, **2019**, 13, 10-21	0.4	
51	Impact of Switching to Fingolimod Versus Injectable Disease-Modifying Therapy Cycling on Risk of Multiple Sclerosis-Related Relapses: A Retrospective Analysis. *International Journal of MS Care*, **2021**, 23, 73-78	2.3	
50	Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis. *BMJ Open*, **2021**, 11, e051509	3	
49	Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2. *International Journal of Physiology, Pathophysiology and Pharmacology*, **2019**, 11, 105-114	3.4	26
48	Use of induced pluripotent stem cells to model inflammatory neurodegeneration and repair in multiple sclerosis. **2022**, 31-43		
47	GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35. *Pharmaceuticals*, **2021**, 14,	5.2	0
46	The need for a strategic therapeutic approach: multiple sclerosis in check.. *Therapeutic Advances in Chronic Disease*, **2022**, 13, 20406223211063032	4.9	4
45	Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy.. *Degenerative Neurological and Neuromuscular Disease*, **2022**, 12, 1-21	5.4	
44	Escalation vs. Early Intense Therapy in Multiple Sclerosis.. *Journal of Personalized Medicine*, **2022**, 12,	3.6	0
43	Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis.. *Expert Review of Clinical Immunology*, **2022**,	5.1	
42	A multicenter study to evaluate the disease burden and health economics of inpatients with multiple sclerosis in China.. *Multiple Sclerosis and Related Disorders*, **2022**, 60, 103732	4	
41	Real-World Comparative Cost-Effectiveness Analysis of Different Classes of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in Saudi Arabia.. *International Journal of Environmental Research and Public Health*, **2021**, 18,	4.6	0
40	Treatment With Cladribine Selects IFNⴲIL17+ T Cells in RRMS Patients - An Study.. *Frontiers in Immunology*, **2021**, 12, 743010	8.4	0
39	System-Level Variation in Multiple Sclerosis Disease-Modifying Therapy Utilization: Findings From the Multiple Sclerosis Continuous Quality Improvement Research Collaborative.. **2021**, 25,		
38	Data_Sheet_1.PDF. **2020**,		
37	Image_1.TIFF. **2020**,		
36	Image_10.TIFF. **2020**,		
35	Image_11.TIFF. **2020**,		

34	Image_12.TIFF. **2020**,		
33	Image_13.TIFF. **2020**,		
32	Image_2.TIFF. **2020**,		
31	Image_3.TIFF. **2020**,		
30	Image_4.TIFF. **2020**,		
29	Image_5.TIFF. **2020**,		
28	Image_6.TIFF. **2020**,		
27	Image_7.TIFF. **2020**,		
26	Image_8.TIFF. **2020**,		
25	Image_9.TIFF. **2020**,		
24	Table_1.DOCX. **2020**,		
23	Table_2.DOCX. **2020**,		
22	Table_3.DOCX. **2020**,		
21	Table_4.xlsx. **2020**,		
20	Fecal microbiota transplantation is safe and tolerable in patients with multiple sclerosis: A pilot randomized controlled trial.. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2022**, 8, 20552173221086662	2	0
19	A Cross-Sectional Analysis of Persistence to Disease-Modifying Therapies in Treatment Naïve and Experienced Patients with Relapsing Multiple Sclerosis at a Health-System Specialty Pharmacy. *Multiple Sclerosis and Related Disorders*, **2022**, 103860	4	
18	Clinical Staging of Alzheimer's Disease: Concordance of Subjective and Objective Assessments in the Veteran's Affairs Healthcare System. *Neurology and Therapy*,	4.6	0
17	Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection. *Multiple Sclerosis and Related Disorders*, **2022**, 104067	4	1

16	Electronic Health Diary Campaigns to Complement Longitudinal Assessments in Persons With Multiple Sclerosis: Nested Observational Study (Preprint).	
15	Serum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-□ **2022**, 12,	
14	Next-Generation Personalized Medicine: Implementation of Variability Patterns for Overcoming Drug Resistance in Chronic Diseases. **2022**, 12, 1303	1
13	Development of PLGA Nanoparticles with a Glycosylated Myelin Oligodendrocyte Glycoprotein Epitope (MOG35∄5) against Experimental Autoimmune Encephalomyelitis (EAE).	0
12	Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases. 13,	0
11	Dysregulation of miR-193a serves as a potential contributor to MS pathogenesis via affecting RhoA and Rock1. **2023**, 69, 104468	0
10	Fecal Microbiota Transplantation and Other Gut Microbiota Manipulation Strategies. **2022**, 10, 2424	1
9	Patients with multiple sclerosis choose a collaborative role in making treatment decision: results from the Italian multicenter SWITCH study. **2022**, 104474	0
8	Paradigm shifts in multiple sclerosis management: Implications for daily clinical practice. **2023**,	0
7	Regulatory T cell therapy for multiple sclerosis: Breaching (blood-brain) barriers. **2022**, 18,	0
6	In vivo corneal confocal microscopy in multiple sclerosis: Can it differentiate disease relapse in multiple sclerosis?. **2023**,	0
5	In silico repurposing of CNS drugs for multiple sclerosis. **2023**, 73, 104622	0
4	S1PR1 modulators in multiple sclerosis: Efficacy, safety, comparison, and chemical structure insights. **2023**, 250, 115182	0
3	Co-occurrence of Multiple Sclerosis and Severe Aplastic Anemia: A Report of Two Cases Successfully Treated with Allogeneic Hematopoietic Stem Cell Transplantation.	0
2	Exploring physicians□prescribing behavior in patients with multiple sclerosis in Saudi Arabia: a sequential explanatory mixed-methods. **2023**, 23,	0
1	Therapeutic Implications of Some Natural Products for Neuroimmune Diseases: A Narrative of Clinical Studies Review. **2023**, 2023, 1-18	0